The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
about
Update on the development of lurasidone as a treatment for patients with acute schizophreniaManagement of bipolar I depression: clinical utility of lurasidoneAntipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia.Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.Lurasidone for schizophrenia: what's different?Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins.Lurasidone : in the treatment of schizophrenia.The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.Potential use of lurasidone for the treatment of bipolar psychosis.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats.Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice.
P2860
Q27009585-7AECB865-B36D-4A8A-991E-60DDB69520DBQ27012673-EF91CBB0-EEC0-43B6-B9FD-FE219C359C73Q33605869-758430C7-850B-4D4A-ABE3-800445A60084Q34542303-088B0071-08D5-4EC9-BC6B-F5C636143201Q36096029-EE657C4A-ACBF-4854-8F55-B019F6888C03Q36486035-54A0501C-DCB5-476F-9619-E2292092F3E7Q37987985-A4385D7E-B3C2-46BB-88F2-ECE1B0EE5E3BQ38024032-E8637F97-9A32-4DC5-9995-FFB21350BDC7Q38069538-1292FC6A-99AA-4787-BF5B-D3BE2B717736Q38120295-EFE839B7-0E88-4CE5-8060-ACD2B940BDE8Q38149953-A69E222C-D841-45E0-ADEC-55562EC08FDBQ38336677-079893AD-E039-42D4-8052-0E5B7F47A311Q38546598-690E6EA3-993F-4314-9599-69E8274867E7Q47970781-8424E1BF-BD4A-4284-B563-5635535FE93CQ48288448-D3FAD8A7-61EF-4FBA-A57B-6722CA5F5D9DQ50550002-7C2E93FE-DC9D-4C16-9072-446D2C70876A
P2860
The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@ast
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@en
type
label
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@ast
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@en
prefLabel
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@ast
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@en
P2093
P2860
P356
P1476
The novel antipsychotic drug l ...... r-mediated synaptic responses.
@en
P2093
Eunice Y Yuen
Herbert Y Meltzer
Masakuni Horiguchi
Xiangning Li
P2860
P304
P356
10.1124/MOL.111.076141
P577
2011-11-09T00:00:00Z